ArticleBiotechnology for biofuels and bioproducts2025
Enhancing selective itaconic acid synthesis in Yarrowia lipolytica through targeted metabolite transport reprogramming.
Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitochondrial and plasma‑membrane transport‑based engineering enables industrial‑level isocitric acid production in Yarrowia lipolytica.Microbial cell factories · 2026Article
- Biosynthetic Gene Cluster Diversity and Species-Specific Metabolic Potential in Ustilaginaceae.Journal of fungi (Basel, Switzerland) · 2026Article
- Extracellular Phosphate Availability ImpactsJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundItaconic acid is a valuable platform chemical with applications in polymer synthesis and other industrial sectors. Microbial fermentation offers a sustainable production route, involving two fungi such as Aspergillus terreus and Ustilago maydis. However, their employment in industrial bioprocesses for itaconic acid production is characterized by several challenges. Yarrowia lipolytica is a non-conventional yeast that shows suitability for industrial production and it is widely employed as heterologous host to obtain relevant metabolites. This study aimed to engineer Y. lipolytica for the selective production of itaconic acid by optimising intracellular metabolic fluxes and transport mechanisms.
resultsA metabolic engineering strategy was developed to prevent the secretion of citric and isocitric acids by blocking their transport at both mitochondrial and plasma membrane levels in Y. lipolytica strains. Specifically, the inactivation of YlYHM2 and YlCEX1 genes reduced secretion of citric and isocitric acid, enabling their accumulation in the mitochondria. Additionally, heterologous transporters from Aspergillus terreus (mttA and mfsA) and Ustilago maydis (mtt1 and itp1) were introduced to enhance the mitochondrial export of cis-aconitate and the extracellular secretion of itaconic acid. For the first time, complete gene set of the itaconate biosynthetic pathways from both fungal species were functionally expressed and compared in a yeast system with a similar genetic background. A synergistic increase in itaconic acid production was observed when both pathways were co-expressed, combined with the inactivation of native citric and isocitric transport. In contrast to previously engineered Y. lipolytica strains for itaconic acid production, the optimised strain obtained in this study does not require complex or nutrient-rich media, while achieving the highest product yield (0.343 mol IA/mol glucose) and productivity (0.256 g/L/h) reported in yeast, with minimal by-product formation.
conclusionsBy integrating transporter engineering and pathway diversification, this study demonstrates an effective strategy to enhance itaconic acid production in Y. lipolytica while minimising by-product formation. The findings provide new insights into organic acid transport in yeast and open avenues for further optimization of microbial cell factories for sustainable biochemical production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.